Literature DB >> 11494162

Interleukin-18 inhibits human immunodeficiency virus type 1 production in peripheral blood mononuclear cells.

H J Choi1, C A Dinarello, L Shapiro.   

Abstract

Interleukin (IL)-18 is an interferon (IFN)-gamma-inducing factor and contributes to the Th1 immune response. IL-18 added after infection of peripheral blood mononuclear cells (PBMC) with monocyte-tropic human immunodeficiency virus type 1 (HIV-1) inhibited p24 antigen production by a maximum of 72%. IFN-gamma levels in these cultures were increased, and a significant inverse relationship between HIV-1 production and IFN-gamma levels was observed. A neutralizing anti-IFN-gamma antibody reversed the IL-18 inhibitory effect. Preincubation of PBMC with IL-18 before infection inhibited p24 without additional IL-18 (64%). However, compared with the degree of IL-18 inhibition observed after a 4-day culture, no additional IL-18 inhibitory effect was observed during days 5-13. IL-18 also reduced cell surface expression of the HIV-1 receptor CD4. These results demonstrate that IL-18 inhibited HIV-1 production in PBMC through intermediate IFN-gamma. Furthermore, inhibition was present during the early stages of viral infection and was associated with reduced HIV-1 receptor expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494162     DOI: 10.1086/322805

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  New players in cytokine control of HIV infection.

Authors:  Massimo Alfano; Andrea Crotti; Elisa Vicenzi; Guido Poli
Journal:  Curr HIV/AIDS Rep       Date:  2008-02       Impact factor: 5.071

2.  IL-18 gene promoter polymorphism is involved in HIV-1 infection in a Brazilian pediatric population.

Authors:  Ludovica Segat; Daiana Bevilacqua; Michele Boniotto; Luiz C Arraes; Paulo R de Souza; Josè L de Lima Filho; Sergio Crovella
Journal:  Immunogenetics       Date:  2006-05-05       Impact factor: 2.846

3.  In vitro suppression of human immunodeficiency virus type 1 replication by measles virus.

Authors:  Mayra García; Xiao-Fang Yu; Diane E Griffin; William J Moss
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Serum and cerebrospinal fluid levels of interleukin-18 in human immunodeficiency virus type 1-associated central nervous system disease.

Authors:  Hans-Jürgen von Giesen; Sebastian Jander; Hubertus Köller; Gabriele Arendt
Journal:  J Neurovirol       Date:  2004-12       Impact factor: 2.643

5.  Gene Expression and Antiviral Activity of Interleukin-35 in Response to Influenza A Virus Infection.

Authors:  Li Wang; Shengli Zhu; Gang Xu; Jian Feng; Tao Han; Fanpeng Zhao; Ying-Long She; Shi Liu; Linbai Ye; Ying Zhu
Journal:  J Biol Chem       Date:  2016-06-15       Impact factor: 5.157

6.  Inducible GBP5 Mediates the Antiviral Response via Interferon-Related Pathways during Influenza A Virus Infection.

Authors:  Jian Feng; Zhongying Cao; Li Wang; Yushun Wan; Nanfang Peng; Qing Wang; Xueyuan Chen; Yaqin Zhou; Ying Zhu
Journal:  J Innate Immun       Date:  2017-04-05       Impact factor: 7.349

Review 7.  The macrophage in HIV-1 infection: from activation to deactivation?

Authors:  Georges Herbein; Audrey Varin
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

8.  Constitutive expression of interleukin-18 and interleukin-18 receptor mRNA in tumour derived human B-cell lines.

Authors:  S L Lorey; Y C Huang; V Sharma
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

9.  Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1-infected patients.

Authors:  E Stylianou; V Bjerkeli; A Yndestad; L Heggelund; T Waehre; J K Damås; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

10.  Interleukin 18 and human immunodeficiency virus type I infection in adolescents and adults.

Authors:  W Song; C M Wilson; S Allen; C Wang; Y Li; R A Kaslow; J Tang
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.